LNTH Stock Surges 13% With A 9-day Winning Spree On Institutional Accumulation

LNTH: Lantheus logo
LNTH
Lantheus

Lantheus (LNTH) – a developer of diagnostic and therapeutic imaging agents – hit a 9-day winning streak, with cumulative gains over this period amounting to 13%. The company’s market cap has surged by about $559 Mil over the last 9 days and currently stands at $4.9 Bil.

The stock has YTD (year-to-date) return of 10.0% compared to 0.2% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.

What Triggered The Rally?

[1] Sustained Institutional Accumulation

Relevant Articles
  1. Decoding PLTR Stock’s Premium Valuation
  2. Intuit Stock: Strong Cash Flow Poised for a Re-Rating?
  3. Five-Year Tally: Lowe’s Companies Stock Delivers $50 Bil Gain
  4. Five-Year Tally: Mastercard Stock Delivers $60 Bil Gain
  5. Palantir Technologies Stock Hits Key Support – Buying Opportunity?
  6. Stronger Bet Than Ross Stores Stock: BURL, URBN Deliver More

  • Significant New Stakes by Large Funds
  • Institutional Ownership at 99%
  • Impact: Increased Investor Confidence, Sustained Upward Price Movement

[2] Technical Breakout

  • Price Crossed Above 50-Day Moving Average
  • 50-Day MA Crossed Above 200-Day MA
  • Impact: Shift From Downward to Upward Trend, Long-term Bullish Signal

Opportunity or Trap?

Below is our take on valuation.

There are only a couple of things to fear in LNTH stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell LNTH).

But here is the real interesting point.

You are reading about this 13% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.

Trefis

Returns vs S&P 500

The following table summarizes the return for LNTH stock vs. the S&P 500 index over different periods, including the current streak:

Return Period LNTH S&P 500
1D 0.2% -0.3%
9D (Current Streak) 12.8% 0.9%
1M (21D) 11.1% 1.0%
3M (63D) 39.4% 2.8%
YTD 2026 10.0% 0.2%
2025 -25.6% 16.4%
2024 44.3% 23.3%
2023 21.7% 24.2%

However, big gains can follow sharp reversals – but how has LNTH behaved after prior drops? See LNTH Dip Buyer Analysis to learn more.

Gains and Losses Streaks: S&P 500 Constituents

There are currently 42 S&P constituents with 3 days or more of consecutive gains and 47 constituents with 3 days or more of consecutive losses.
 

Consecutive Days # of Gainers # of Losers
3D 13 35
4D 23 5
5D 5 5
6D 0 2
7D or more 1 0
Total >=3 D 42 47

 
 
Key Financials for Lantheus (LNTH)

Last 2 Fiscal Years:

Metric FY2023 FY2024
Revenues $1.3 Bil $1.5 Bil
Operating Income $364.6 Mil $448.6 Mil
Net Income $326.7 Mil $312.4 Mil

Last 2 Fiscal Quarters:

Metric 2025 FQ2 2025 FQ3
Revenues $378.0 Mil $384.0 Mil
Operating Income $88.0 Mil $43.6 Mil
Net Income $78.8 Mil $27.8 Mil

While LNTH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.